Silence Therapeutics (SLN) EBIAT: 2020-2025
Historic EBIAT for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$21.0 million.
- Silence Therapeutics' EBIAT rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 22.49%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' EBIAT is -$21.0 million, which was up 23.38% from -$27.4 million recorded in Q2 2025.
- Over the past 5 years, Silence Therapeutics' EBIAT peaked at $12.3 million during Q4 2024, and registered a low of -$13.6 billion during Q1 2021.
- Its 3-year average for EBIAT is -$16.0 million, with a median of -$15.4 million in 2023.
- As far as peak fluctuations go, Silence Therapeutics' EBIAT skyrocketed by 224.58% in 2024, and later tumbled by 1,134.00% in 2025.
- Over the past 5 years, Silence Therapeutics' EBIAT (MRQ) stood at -$6.4 million in 2021, then crashed by 48.71% to -$9.6 million in 2022, then fell by 3.03% to -$9.9 million in 2023, then surged by 224.58% to $12.3 million in 2024, then plummeted by 270.36% to -$21.0 million in 2025.
- Its EBIAT was -$21.0 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$28.5 million in Q1 2025.